Table 1.

Differences in demographics and clinical characteristics during the acute SARS-CoV-2 infection between patients with persistent symptoms at follow-up and patients recovered.

	Study population (n = 75)	Patients recovered (n = 29)	Patients with persistence of symptoms (PCC children) (n = 46)	p
Gender, n (%) Female	37 (49.3%)	13 (44.8%)	24 (52.2%)	0.8
Age (y), median IQR	10.2 (4.9)	10.1 (3)	10.5 (6.7)	0.34
Follow-up (months), median IQR	3.3 (4.6)	3.1 (6)	3.6 (4.4)	0.9
Comorbidities, n (%)	6 (8%)	2 (6.9%)	4 (8.7%)	1
Disease severity, n (%)
Asymptomatic	4 (5.3%)	2 (6.9%)	2 (4.3%)	0.3
Mild	60 (80%)	25 (86.2%)	35 (76.1%)
Moderate/severe	11 (14.7%)	2 (6.9%)	9 (19.6%)
Hospitalization, n (%)	7 (9.3%)	2 (6.9%)	5 (10.9%)	0.7
PICU hospitalization, n (%)	2 (2.7%)	1 (3.4%)	1 (2.2%)	1
Number of symptoms, n (%) median IQR	3 (3)	2 (2)	4 (4)	0.005
Fever, n (%)	52 (69.3%)	17 (58.6%)	35 (76%)	0.1
Days of fever, median IQR	2 (3)	1 (2)	2 (3)	0.002
Rhinitis, n (%)	27 (36%)	12 (41.4%)	15 (32.6%)	0.4
Anosmia, n (%)	22 (29.3%)	5 (17.2%)	17 (37%)	0.06
Dysgeusia, n (%)	18 (24%)	5 (17.2%)	13 (28.3%)	0.2
Cough, n (%)	27 (36%)	8 (27.6%)	19 (41.3%)	0.22
Dyspnea at rest, n (%)	4 (5.3%)	1 (3.4%)	3 (6.5%)	1
Dyspnea under exertion, n (%)	5 (6.7%)	1 (3.4%)	4 (8.7%)	0.6
Asthma, n (%)	2 (2.7%)	0 (0%)	2 (4.3%)	0.5
Chest pain, n (%)	7 (9.3%)	1 (3.4%)	6 (13%)	0.23
Joint pain, n (%)	12 (16%)	1 (3.4%)	11 (23.9%)	0.02
Muscle pain, n (%)	19 (25.3%)	2 (6.9%)	17 (37%)	0.005
Asthenia, n (%)	28 (37.3%)	7 (24.1%)	21 (45.7%)	0.06
Headache, n (%)	31 (41.3%)	10 (34.5%)	21 (45.7%)	0.33
GI disorders, n (%)	10 (13.3%)	1 (3.4%)	9 (19.6%)	0.07
Rash, n (%)	6 (8%)	1 (3.4%)	5 (10.9%)	0.39

ICU intensive care unit, GI gastrointestinal.